Analysis of tumor-rejecting biological reactions induced by tumor specific immune responses

肿瘤特异性免疫反应诱导的肿瘤排斥生物反应分析

• 批准号: 23300355
• 负责人: TAKEDA Kazuyoshi
• 金额: $ 14.14万
• 依托单位: Juntendo University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011-04-01 至 2014-03-31
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23300355/
• 关键词: 免疫監視; 腫瘍免疫; 癌治療; 免疫エスケープ; NK細胞; 腫瘍特異的 CTL; 免疫; 抗体療法; TRAIL; DR5; 癌抗原; 癌ワクチン療法; CTL; IFN-γ; 肺転移; 血管閉塞; 細胞傷害活性

This study was aiming to reveal the immune responses induced in tumor mass and tumor-rejecting biological responses induced by specific anti-tumor immune responses. I have reported that (1) Critical roles of IFN-gamma produced by primarily infiltrating NK cells for entire anti-tumor immune responses (2) Immune suppression by MHC Class II-dressed NK cells (3) novel therapy basing on the specific phenotypic changes of tumor infiltrating CTLs. I am now going to prepare the reports concerning the mechanisms that immune responses induce resistance against anti-tumor immune responses in targeted-tumor cells and the biological responses specifically induced in the rejected tumor mass.

本研究旨在揭示肿瘤组织中诱导的免疫反应以及特异性抗肿瘤免疫反应诱导的肿瘤排斥生物学反应。我已经报道了（1）主要由浸润NK细胞产生的IFN-γ在整个抗肿瘤免疫应答中的关键作用（2）MHC II类修饰的NK细胞的免疫抑制（3）基于肿瘤浸润CTL的特异性表型变化的新疗法。我现在准备的报告涉及免疫应答诱导靶向肿瘤细胞对抗肿瘤免疫应答的抗性的机制，以及在被排斥的肿瘤块中特异性诱导的生物学应答。

项目成果

2) A phase 1 clinical trial with KIF20A peptide in combination with gemcitabine for advanced pancreatic cancer patients.切除不能・進行膵癌に対する新規膵癌ペプチドワクチンとゲムシタビン塩酸塩を用いた第1相試験

2）KIF20A肽联合吉西他滨用于晚期胰腺癌患者的1期临床试验，使用新型胰腺癌肽疫苗和盐酸吉西他滨治疗不可切除/晚期胰腺癌。

• 发表时间: 2013
• 作者: 鈴木伸明;硲彰一;上野富雄;吉野茂文;竹田和由;中村祐輔;岡正朗
• 通讯作者: 岡正朗

Importin β1 Protein-mediated Nuclear Localization of Death Receptor 5 (DR5) Limits DR5/Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-induced Cell Death of Human Tumor Cells

• DOI: 10.1074/jbc.m111.309377
• 发表时间: 2011-12-16
• 期刊: JOURNAL OF BIOLOGICAL CHEMISTRY
• 影响因子: 4.8
• 作者: Kojima, Yuko;Nakayama, Masafumi;Yagita, Hideo
• 通讯作者: Yagita, Hideo

A phase 1 clinical trial with KIF20A peptide in combination with gemcitabine for advanced pancreatic cancer patients

KIF20A肽联合吉西他滨治疗晚期胰腺癌的1期临床试验

• 发表时间: 2013
• 作者: 柴田 智博;渡 公佑;河原 明彦;村上 雄一;鍋島 弘嗣;東 公一;鹿毛 政義;向田 直史;桑野 信彦;高橋 隆;小野 眞弓;鈴木伸明
• 通讯作者: 鈴木伸明

CD1d-restricted natural killer T cells contribute to hepatic inflammation and fibrogenesis in mice

• DOI: 10.1016/j.jhep.2010.08.022
• 发表时间: 2011-06-01
• 期刊: JOURNAL OF HEPATOLOGY
• 影响因子: 25.7
• 作者: Ishikawa, Sachiko;Ikejima, Kenichi;Watanabe, Sumio
• 通讯作者: Watanabe, Sumio

Local effects of regulatory T cells in MUC1 transgenic mice potentiate growth of MUC1 expressing tumor cells in vivo.

• DOI: 10.1371/journal.pone.0044770
• 发表时间: 2012
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Sugiura D;Denda-Nagai K;Takashima M;Murakami R;Nagai S;Takeda K;Irimura T
• 通讯作者: Irimura T